1 / 23

CYP2C8 and Drug Interactions

FDA Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee meeting, November 18. 2003, Rockville, MD. CYP2C8 and Drug Interactions.

clifford
Download Presentation

CYP2C8 and Drug Interactions

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. FDA Advisory Committee for Pharmaceutical SciencesClinical Pharmacology Subcommittee meeting, November 18. 2003, Rockville, MD CYP2C8 and Drug Interactions Pertti J. Neuvonen, MD Department of Clinical Pharmacology University of Helsinki & Helsinki University Central HospitalHelsinki, Finland

  2. Outline • Expression and Substrates of CYP2C8 • Inhibitors of CYP2C8 • Inducers of CYP2C8 • In vivo interaction studies with CYP2C8 substrates • Suggestions for in vitro and in vivo studies

  3. CYP2C8 expression • CYP2C8 is • highly expressed in the liver (CYP2C protein content: CYP2C9 >~ CYP2C8> CYP2C19) • large interindividual variation • not detectable in the intestine (Läpple et al., Pharmacogenetics 2003)

  4. Substrates of CYP2C8 • Paclitaxel (taxol); (-> 6-alpha-OH-paclitaxel) • Amodiaquine (-> N-desethyl-amodiaquine) • Torsemide (-> tolyl-methyl-OH-T; CYP2C9 > CYP2C8) • Cerivastatin (CYP2C8 > CYP3A4) • Repaglinide (CYP2C8 > CYP3A4) • Rosiglitazone (CYP2C8 > CYP2C9) • Several other drugs; Contribution of different CYPs may depend on substrate concentration

  5. Amodiaquine metabolism and paclitaxel 6-alphahydroxylase activity 10 human livers (Li et al., JPET 2002)

  6. Inhibitors of CYP2C8: trimethoprim • Trimethoprim • competitive inhibitor of CYP2C8 (Ki 32 µM), relatively selective up to 100 µM

  7. Inhibition of CYPs by trimethoprim CYP2C8 (Ki 32 µM) (Wen et al., DMD 2002)

  8. Inhibition of CYPs by trimethoprim (Wen et al., DMD 2002)

  9. Inhibitors of CYP2C8 • Trimethoprim • Quercetin • competitive inhibitor of CYP2C8 (Ki 2 µM), inhibits also CYP1A2 • ”Glitazones” (thiazolidinediones) • Gemfibrozil; nonselective; in vitro and in vivo • Other nonselective inhibitors

  10. Ki values for glitazones CYP2C8 CYP2C9 CYP3A4 Rosiglitazone 5.59 29.9 36.3 Pioglitazone 1.69 32.1 11.8 Troglitazone 2.59 0.63 1.6 (Sahi et al., DMD 2003) (Ki values, microM)

  11. Inhibition of CYP2C8 by prototypic CYP isoform ”selective” probes Diethyldithiocarbamate also CYP2C8 inhibitor CYP2E1 Ketoconazole also CYP2C8 inhibitor CYP3A (Ong et al., BrJCp 2000)

  12. Induction of CYP2C8 • In vitro: CYP2C8 is inducible • Rifampin: CYP2C8 >CYP2C19, CYP2C9 • Rifampin>Phenobarb.>Dexamethasone (Raucy et al., JPET 2002) • In vivo: Rifampin decreases the AUC of repaglinide by about 60% (30-78%) (Niemi et al., CPT 2000)

  13. In vivo studies: Gemfibrozil + Statins / Oral Antidiabetics • Randomized, cross-over, healthy volunteers • Gemfibrozil 1200 mg/d or placebo/comparator for 3-4 days • On day 3, a single dose of • Cerivastatin • Simvastatin • Lovastatin (Gemfibrozil, Bezafibrate, Placebo) • Repaglinide (Gemfibr., Itraconazol, Gem+Itra, Plac) • Rosiglitazone

  14. Effect of gemfibrozil on cerivastatin PK Cerivastatin (acid) Cerivastatin lactone AUC x 5-6 M-23 metabolite CYP2C8 M-1 metabolite CYP3A4 (Backman et al. CPT 2002)

  15. Gemfibrozil inhibits cerivastatin metabolism (CYP2C8) in vitro Rate of metabolite formation M23; CYP2C8 (Wang et al. DMD 2002)

  16. Gemfibrozilincreases the AUC of simvastatin acid but NOT of the parent simvastatin Gemfibrozil: Simvastatin acid: AUC x 2.3 Simvastatin AUC: ~ Placebo (Backman et al. CPT 2000)

  17. corresponding (active) acids CYP-enzymes in simvastatin metabolism Carboxyl-esterase Simvastatin (0) CYP3A4, CYP2C8 CYP3A4 Simvastatin acid (100) (Gruer et al., Am J Cardiol 1999; Prueksaritanont et al. BrJCP 2003)

  18. Gemfibrozilunlike bezafibrate increases the AUC of lovastatin acid but NOT of the parent lovastatin Lovastatin AUC: ~ Gemfibrozil 600 mg x 2 Lovastatin acid AUC: x 2.8 Bezafibrate 400 mg x 1 Placebo (Kyrklund et al,. CPT 2001)

  19. Gem+itra Gem 600mg x 2 Itra 200mg x 1 Effect of gemfibrozil, itraconazole and their combination on plasma repaglinide and its M1-metabolite M1-metabolite; CYP3A4 Repaglinide Gem 600mg x 2 Placebo Gem+itra Placebo Itra n (Niemi et al., Diabetologia 2003)

  20. Effect of CYP3A4 inhibitors and gemfibrozil on the AUC of repaglinide Repaglinide AUC (Niemi et al. CPT 2001, Diabetologia 2003)

  21. Effect of Gemfibrozil on Rosiglitazone Rosiglitazone AUC x 2.3 Gemfibrozil Placebo (Niemi et al., Diabetologia 2003)

  22. CYP2C8: in vitro interaction studies • Human liver microsomes, or recombinant human CYP2C8 isoform • Substrates: • paclitaxel, amodiaquine • torsemide (only with recombinant CYP2C8) • Inhibitors: • trimethoprim, quercetin, pio/rosiglitazone • Inducers: • rifampin

  23. CYP2C8: in vivo interaction studies • Probe substrates: • repaglinide (obs. hypoglycemia) • rosiglitazone • cerivastatin? (availability?); amodiaquine?? (toxic) • Inhibitors: • gemfibrozil (nonselective, e.g. CYP2C9 and OATP2) • trimethoprim (in vivo data as inhibitor?) • pio/rosiglitazone (in vivo data as inhibitors?) • Inducers: rifampin (nonselective) • Further studies are needed to find optimal probe substrates and inhibitors, particularly for in vivo interaction studies

More Related